Table 3. Correlation of HIF-1α, MDR1, and LAPTM4B expression with clinico-pathological features of ovarian cancer.
| Clinical-pathological Characteristics | ALL N (%) |
HIF-1α expression | MDR1 expression | LAPTM4B expression | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | p-value | Low | High | p-value | Low | High | p-value | |||
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | ||||||
| Age | 0.700 | 0.181 | 0.115 | ||||||||
| <50 | 26 (61.9) | 7 (26.9) | 19 (73.0) | 11 (42.3) | 15 (57.6) | 9 (34.6) | 17 (65.3) | ||||
| >50 | 16 (38.0) | 3 (18.7) | 13 (81.2) | 4 (25.0) | 12 (75.0) | 3 (18.7) | 13 (81.2) | ||||
| Stage | 0.030 | 0.010 | 0.001 | ||||||||
| I–II | 12 (28.5) | 4 (33.3) | 8 (66.6) | 7 (58.3) | 5 (41.6) | 6 (50.0) | 6 (50.0) | ||||
| III–IV | 30 (71.4) | 6 (20.0) | 24 (80.0) | 8 (26.6) | 22 (73.3) | 6 (20.0) | 24 (80.0) | ||||
| Metastasis | 0.015 | 0.028 | 0.005 | ||||||||
| Metastatic | 28 (66.6) | 6 (21.4) | 24 (85.7) | 9 (32.1) | 19 (67.8) | 7 (25.0) | 21 (75.0) | ||||
| Non-Metastatic | 14 (33.3) | 4 (28.5) | 8 (57.1) | 6 (42.8) | 8 (57.1) | 5 (35.7) | 9 (64.2) | ||||
| Chemotherapy Status | 0.018 | 0.012 | 0.036 | ||||||||
| Treatment naive | 8 (19.0) | 5 (62.5) | 3 (37.5) | 5 (62.5) | 3 (37.5) | 6 (75.0) | 2 (25.0) | ||||
| pre-treated | 34 (80.9) | 5 (14.7) | 29 (85.2) | 10 (29.4) | 24 (70.5) | 6 (17.6) | 28 (82.4) | ||||
Notes:
The N shows the number of patients in each group. Where p value describes the significance and p < 0.05 shows the significance of results.